शुभ दीपावलीDiwali offer: 3 months free on yearly plans · ends 11 NovSee plans
FDCBSEFDC Ltd· Pharmaceuticals & BiotechnologyHighNeutral
Announced Wed, 27 May, 2026 · 15:24 IST

Approved Standalone and consolidated financial results for the financial year ending March 31, 2026

FDC · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
+5.1%Reaction day
₹401.60
prior close
₹425.00
announcement price
In-mkt
timing
Nifty Microcap 250market · in no size index; the smallest one is used-0.0%+5.1% vs market
Pharmaceuticals peers, median of 164sector+0.1%+5.0% vs sector

On the reaction day the stock moved 5.1 pts more than Nifty Microcap 250 and 5.0 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
-0.7
10m
—
15m
—
30m
—
Sessions after the filingfrom the prior close
StockMarketvs marketSectorvs sector
Reaction day
+5.1-0.0+5.1+0.1+5.0
Next day
+0.3-0.7+1.0-0.6+0.9
2d
-2.9-1.8-1.1-1.3-1.6
3d
-1.3-0.7-0.6-1.4+0.1
4d
-0.5-0.5-0.1-1.6+1.0
5d
+0.2+0.4-0.2-0.6+0.8
1w
-4.6-1.6-3.1-2.3-2.4
15d
-4.0+4.6-8.7+0.0-4.0
1m
+4.1+4.6-0.5+3.0+1.1
2m
+3.8+6.1-2.3+4.4-0.5
3m
-14.4+10.8-25.2+8.6-23.0
UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 164Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

FDC Limited reported annual revenue of Rs. 2,126 crore (standalone), up 2.7% from Rs. 2,070 crore last year. Net profit after tax grew 4.5% to Rs. 285.92 crore from Rs. 273.63 crore. Basic EPS improved to Rs. 17.56 from Rs. 16.81. Consolidated revenue was Rs. 2,170 crore with PAT of Rs. 281.42 crore. An exceptional charge of Rs. 20.79 crore was recognized due to new Labour Codes (non-recurring). Operating cash flow declined significantly to Rs. 200 crore from Rs. 310 crore last year. The statutory auditors issued an unmodified (clean) opinion. The Board also re-appointed Cost Auditor and Tax Auditor for FY27.

Likely market impact

Solid profitability growth and clean audit support the stock, but the sharp decline in operating cash flow (down 35%) and modest revenue growth of under 3% may concern investors looking for higher growth momentum.